CROI 2015 Program and Abstracts

Poster Listings

WEDNESDAY, FEBRUARY 25, 2015 Session P-I1 Poster Session

TUESDAY, FEBRUARY 24, 2015 Session P-J1 Poster Session

Poster Hall

Poster Hall

2:30 pm– 4:00 pm Drug Development 536 Inhibition of HIV-1 Replication by a Novel Acylguanidine-Based Molecule Philip Mwimanzi 1 ; IanTietjen 2 ; Aniqa Shahid 1 ; Scott C. Miller 2 ; David Fedida 2 ; Zabrina L. Brumme 1 ; Mark Brockman 1 1 Simon Fraser University, Burnaby, Canada; 2 University of British Columbia, Vancouver, Canada 537 4’-Ethynyl-2-Fluoro-2’-Deoxyadenosine (EFdA) Has an Extremely High Genetic Barrier, Persistently Exerting Highly Potent Activity Against a Variety of HIV-1 Isolates Including EFdA-Selected HIV-1 Variants Kenji Maeda 1 ;YukiTakamatsu 1 ; Satoru Kohgo 2 ; Nicole S. Delino 1 ; Simon B. Chang 1 ; Kazuhiro Haraguchi 3 ; Hiroaki Mitsuya 1 1 National Institutes of Health (NIH), Bethesda, MD, US; 2 National Center for Global Health and Medicine, Tokyo, Japan; 3 Nihon Pharmaceutical University, Saitama, Japan 538 GSK2838232, a Second Generation HIV-1 Maturation Inhibitor With an Optimized Virology Profile Jerry Jeffrey 1 ; PingWang 1 ; Charlene McDanal 1 ; Pauline J. Shipper 2 ; Kevin Brown 1 ; Cristin Galardi 1 ; JunTang 1 ; Monique Nijhuis 2 ; Brian Johns 1 1 GlaxoSmithKline, Research Triangle Park, NC, US; 2 University of Utrecht, Utrecht, Netherlands 539 Maturation Inhibitor Mechanistic Studies - Differential Inhibition of Gag Polymorphs Zeyu Lin 1 ; Joseph Cantone 1 ;Tricia Protack 1 ; Dieter Drexler 1 ; Beata Nowicka-Sans 1 ;YuanTian 3 ; Zheng Liu 1 ; Mark Krystal 1 ; Alicia Regueiro-Ren 1 ; Ira B. Dicker 1 1 Bristol-Myers Squibb Co, Wallingford, CT, US; 2 Bristol-Myers Squibb Co, Wallingford, CT, US; 3 Bristol-Myers Squibb Co, Princeton, NJ, US; 4 Bristol-Myers Squibb Co, Wallingford, CT, US 540 Late-Stage Integrase-LEDGF Inhibitors Mode of Action and Acquisition of Resistance Richard Benarous 1 ; Erwann Le Rouzic 1 ; Nikki van Bel 2 ;YmeVan derVelden 2 ; Damien Bonnard 1 ; Atze Das 2 ; Celine Amadori 1 ; Alessia Zamborlini 4 ; Stephane Emiliani 3 ; Ben Berkhout 2 1 BiodimMutabilis, Romainville, France; 2 Academic Medical centre, Amsterdam, Netherlands; 3 Inserm CNRS, Paris, France; 4 U944 UMR7212, Inserm CNRS, Paris, France On behalf of the University ofWashington-Dakar HIV-2 Study Group 1 University of Washington, Seattle, WA, US; 2 CHNU de Fann, Dakar, Senegal 542 Dual Loaded Sustained Release Core-Shell Nanoparticles for Anti-HIV Therapy Hilliard L. Kutscher 1 ; Jessica L. Reynolds 1 ; Faithful Makita 2 ; Sara DiTursi 1 ; Jacob Milling 1 ; Jesse Hanchett 1 ; Charles C. Maponga 2 ; Paras N. Prasad 1 ; Gene D. Morse 1 1 University at Buffalo, Buffalo, NY, US; 2 University of Zimbabwe, College of Health Sciences, Harare, Zimbabwe 543 Chemical Facilitated Endosomal Storage of Long-Acting Antiretroviral Nanoparticles Dongwei Guo; Prasanta K. Dash ; Gang Zhang; Mariluz Arainga; Jaclyn Knibbe; JoEllyn McMillan; Larisa Poluektova; Harris Gelbard; Santhi Gorantla; Howard Gendelman University of Nebraska Medical Center, Omaha, NE, US 541 BMS-986001: A Promising Candidate for HIV-2 Treatment Robert A. Smith 1 ; Dana Raugi 1 ; Kate Parker 1 ; Mariah Oakes 1 ; Papa Salif Sow 2 ; Selly Ba 2 ; Moussa Seydi 2 ; Geoffrey S. Gottlieb 1

2:30 pm– 4:00 pm ART: Recent Perspectives 544 24-Weeks Virologic Efficacy of Fozivudine in ART-Naïve Patients From Africa Arne Kroidl 1 ;Tessa Lennemann 1 ; Frederic Ello 2 ; Jimson Mgaya 3 ; Raoul Moh 2 ; Lucas Maganga 3 ; Serge P. Eholié 2 ; Pierre-Marie Girard 4 ; Friedrich von Massow 5 ; Christine Danel 6 1 Medical Center of the University of Munich (LMU), Munich, Germany; 2 CHU de Treichville, Abidjan, Côte d’Ivoire; 3 NIMR–Mbeya Medical Research Center, Mbeya, United Republic of Tanzania; 4 University Hospital Saint-Antoine, Paris, France; 5 Institute for Life Sciences and Environment GmbH, Heidelberg, Germany; 6 Programme PAC-CI, ANRS, Abidjan, Côte d’Ivoire 545 Attachment Inhibitor Prodrug BMS–663068 in ARV-Experienced Subjects: Week 48 Analysis Melanie Thompson 1 ; Jay Lalezari 2 ; Richard Kaplan 3 ;Yvette Pinedo 4 ; Otto Sussman Pena 5 ; Pedro Cahn 6 ; David A. Stock 7 ; Samit R. Joshi 7 ; George J. Hanna 8 ; Max Lataillade 7 1 AIDS Research Consortium of Atlanta, Atlanta, GA, US; 2 Quest Clinical Research, San Francisco, CA, US; 3 Desmond Tutu HIV Foundation, Cape Town, South Africa; 4 Asociacion Civil Via Libre, Lima, Peru; 5 Asistencia Cientifica de Alta Complejidad SAS, Bogotá, Colombia; 6 Fundacion Huesped, Buenos Aires, Argentina; 7 Bristol-Myers Squibb, Wallingford, CT, US; 8 Bristol-Myers Squibb, Princeton, NJ, US 546 Delay in Antiretroviral Therapy Is Not AssociatedWith Increased Virologic Failure Ashita S. Batavia 1 ; Patrice Severe 2 ; Marc Antoine Jean Juste 2 ; Rode Secours 2 ; Daphne C. Bernard 2 ;William J. Pape 2 ; Daniel Fitzgerald 1 1 Weill Cornell Medical College, New York, NY, US; 2 GHESKIO Center, Port-au-Prince, Haiti 547 Effects of Quadruple First-Line ART on Mucosal Immunity Sergio Serrano-Villar 1 ;Talía Sainz 2 ; Surinder Mann 3 ; Zhong-Min Ma 3 ; Christopher Miller 3 ; Netanya S. Utay 4 ; Basile Siewe 5 ;TaeWook-Chun 6 ; PaoloTroia-Cancio 3 ; David Asmuth 3 1 University Hospital Ramón y Cajal, Madrid, Spain; 2 University Hospital Gregorio Marañón, Madrid, Spain; 3 University of California Davis, Sacramento, CA, US; 4 University of Texas, Galveston, TX, US; 5 Rush University Medical Center, Chicago, IL, US; 6 National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, US 548 Maraviroc-Dependent Pharmacologic Effects on Viral Decay and Immune Recovery in GALT Corbin Thompson 1 ;TaeWook Chun 2 ; Craig Sykes 1 ; Zhing-Min Ma 4 ; Christopher Miller 4 ; Surinder Mann 3 ; Richard Pollard 3 ; Angela Kashuba 1 ; David Asmuth 3 1 University of North Carolina at Chapel Hill, Chapel Hill, NC, US; 2 Division of AIDS, NIAID, NIH, Bethesda, MD, US; 3 University of California Davis Medical Center, Davis, CA, US; 4 University of California Davis, Davis, CA, US 549 Maraviroc Induces HIV Production in RCT and In Vitro, Potentially via the NFkB Pathway Jori Symons 1 ;Ward de Spiegelaere 2 ; AnnemarieWensing 1 ; Julia Drylewicz 3 ; Ananja Middel 4 ; Andy I. Hoepelman 4 ; KikiTesselaar 3 ; LinosVandekerckhove 2 ; Steven F. van Lelyveld 4 ; Monique Nijhuis 1 1 University Medical Center Utrecht, Utrecht, Netherlands; 2 Ghent University, Ghent, Belgium; 3 University Medical Centre Utrecht, Utrecht, Netherlands; 4 University Medical Centre Utrecht, Utrecht, Netherlands 550 Consistency of Dolutegravir Treatment Difference in HIV+ Treatment Naives at Week 96 Catherine M. Granier 1 ; Robert Cuffe 2 ; Louise Martin-Carpenter 3 ; KimberlyY. Smith 3 ; Clare Brennan 4 ; Keith Pappa 4 ; BrianWynne 4 ; Steve Almond 5 ; Naomi Givens 1 ; Michael Aboud 2 1 GlaxoSmithKline, Uxbridge, United Kingdom; 2 ViiV Healthcare, London, United Kingdom; 3 ViiV Healthcare, Research Triangle Park, NC, US; 4 GlaxoSmithKline, Research Triangle Park, NC, US; 5 GlaxoSmithKline, Mississauga, Canada 551 Predictors of HIV RNA Suppression on Darunavir/Ritonavir Monotherapy in the MONET and PROTEA Trials Diego Ripamonti 2 ; Ralph DeMasi 3 ; AndrewM. Hill 1 ; Ceyhun Bicer 4 ; Christiane Moecklinghoff 5 1 Chelsea and Westminster Hospital, London, United Kingdom; 2 A.O. Papa Giovanni XXIII, Bergamo, Italy; 3 Janssen Pharmaceuticals, Inc., Titusville, NJ, US; 4 Janssen Pharmaceuticals, Inc., Beerse, Belgium; 5 Janssen Pharmaceuticals, Inc., Neuss, Germany

Poster Listings

45

CROI 2015